@article {Ahmed2021.10.07.463464, author = {Waseem Ahmed and Rafia Azmat and Abdul Qayyum and Rasheed Ahmed and Sumeira Moin}, title = {Antibiotic and novel compounds manipulation in vitro collagen matrix cells changes extracellular matrix non-complete cell division of fibroblast cells as new dermology technology}, elocation-id = {2021.10.07.463464}, year = {2021}, doi = {10.1101/2021.10.07.463464}, publisher = {Cold Spring Harbor Laboratory}, abstract = {Fibroblasts are several cells that are essential for human skin function and regulation process, the underfeed cells are a further issue of skin disorder the current study was based on isolated novel antibiotics compounds comparison of (Chloramphenicol IV) with the changes of Extracellular matrix (RC), inflammatory cells (SC) and non-complete cell division (ICD) effects on fibroblasts cell changes with the cell wall in structural and morphological changes. The new antibiotic compounds were measured and characters in (FTIR) methods with their functional group{\textquoteright}s analysis of bioactive compounds from Adhatoda vasica and Calotropis procera plants and their effective inhibition concentrations (I C50) extract{\textquoteright}s against tyrosinase conditions with their activity in vitro enzymatic process, both extracts have higher enzymatic inhibition assay was assessed. The fibroblast cells were compared with Chloramphenicol IV antibiotics with extracted compounds the cell wall was indiscretion and complete shape and structural changes were measured. The higher values of Diphenolase (22.5 μg/mL) was noted in Adhatoda vasica while an IC50 value of Monophenolase was 19.16 μg/mL, which is helpful in the treatment of fibroblast cell disorders, were higher in collagenase inhibition assay, elastase inhibition assay, hyaluronidase inhibition assay, tyrosinase inhibition assay process. It was concluded that novel antibiotics compounds from species could act an as effective role in fibroblast were used in future medicines as sources of locations and creams to control various skin diseases and skin disorder management{\textquoteright}s processes.Competing Interest StatementThe authors have declared no competing interest.}, URL = {https://www.biorxiv.org/content/early/2021/10/09/2021.10.07.463464}, eprint = {https://www.biorxiv.org/content/early/2021/10/09/2021.10.07.463464.full.pdf}, journal = {bioRxiv} }